Streetbeat News

SYGGF

Synairgen

http://www.synairgen.com/

Industry

Research and Development in Biotechnology

Open

0.03

Mkt cap

15M

Volume

504

High

0.03

P/E Ratio

-0.97

52-wk high

0.09

Low

0.03

Div yield

N/A

52-wk low

0.02

Synairgen PLC is raising funds to support a phase II clinical trial for SNG001, an inhaled antiviral for critically ill patients on mechanical ventilation due to respiratory viruses.

Portfolio Pulse from

December 21, 2024 | 6:45 am

Synairgen PLC plans to raise up to £25 million to fund the development of its investigational inhaled interferon beta treatment, SNG001. The funding includes a significant subscription and a placing and open offer.

Portfolio Pulse from

December 20, 2024 | 8:15 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.